The Psychedelic Therapies Executive Order

I Glenn Cohen; Holly Fernandez Lynch; AL McGuire

doi:10.1001/jama.2026.11892

July 1, 2026JAMA

The Psychedelic Therapies Executive Order

View at Publisher

Ask AI

Bookmark

Share

Key Points

This viewpoint aims to address the implications of an executive order on psychedelic drug development and clinical integration.
Discusses issues surrounding the ethical integration of psychedelic therapies.
Outlines potential frameworks for the development and approval of psychedelic drugs.
Analyzes evidence-based approaches for clinical care involving psychedelics.
Highlights the need for ethical considerations in the application of psychedelic therapies.
Emphasizes the importance of evidence-based practices in integrating these therapies into clinical settings.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Viewpoint discusses the executive order promoting psychedelic drug integration in clinical care, highlighting ethical concerns.

Abstract

This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cohen et al. (2026) studied this question.

synapsesocial.com/papers/6a4755ae5c29257aa257a9c2 https://doi.org/10.1001/jama.2026.11892

View at Publisher

Ask AI

Bookmark

Share

The Psychedelic Therapies Executive Order

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

The Psychedelic Therapies Executive Order

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading